Seattle Genetics Inc (NASDAQ:SGEN)
During the Trading Day
| 31.49 |  -0.71 / -2.20% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 31.49 |  0.00 / 0.00% |
Volume: 8.4K |
Latest SGEN News | Press Releases
| Takeda, Seattle Genetics Report Data for Adcetris in Malignant Lymphoma Compared to P... 9:23am / Benzinga | SGEN Starts Adcetris Phase I/II Study - Analyst Blog Jun 11 / Zacks.com |
| A Trio of Cancer Immunotherapy Innovators Jun 14 / MotleyFool.com | Acadia Pharmaceuticals Soars On Hedge Fund Investment Jun 10 / MotleyFool.com |
Today’s Trading
| Previous close | 32.20 |
| Today’s open | 32.26 |
| Day’s range | 31.37 - 32.40 |
| Volume | 399,901 |
| Average volume (3 months) | 783,014 |
| Market cap | $3.9B |
| Dividend yield | -- |
Data as of 4:00pm ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | +65.67% |
| Earnings growth (this year) | -82.31% |
| Earnings growth (next 5 years) | +96.00% |
| Revenue growth (last year) | +122.43% |
| P/E ratio | NM |
| Price/Sales | 12.95 |
| Price/Book | 17.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALKSAlkermes Plc | -1.00 | -3.34% |
| JAZZJazz Pharmaceuticals... | -1.38 | -1.98% |
| SLXPSalix Pharmaceutical... | -0.41 | -0.61% |
| MDVNMedivation Inc | -2.17 | -4.45% |
Data as of 4:00pm ET, 06/19/2013
Financials
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $210.8M |
| Annual profit (last year) | -$53.8M |
| Net profit margin | -25.51% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Clay B. Siegall, PhD |
Chief Operating Officer & Secretary Eric L. Dobmeier |
Corporate headquarters Bothell, Washington |
Forecasts
